Gsk Pharma

GSK Pharma stock gains over 3% after profit, revenue boost in Q2 earnings

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday's intraday trade

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion

Lawsuits against the companies began piling up in both state and federal courts after the US Food and Drug Administration in 2020 asked manufacturers to pull Zantac off the market

Valuations may temper gains for GlaxoSmithKline Pharma despite strong Q1

The brokerage has estimated a 9 per cent earnings growth over FY24-26 for GSK Pharma

GSK Pharma Q1 FY25 results: Net profit rises 37%, revenue up 6.9%

GSK Pharma's stocks were up by 2.49 per cent, ending the day's trade at Rs 2,824.45 apiece on the Bombay Stock Exchange (BSE)

New product launches may continue to fuel GSK Pharma's robust growth

GSK Pharma's recent good showing is on expectations that launches in the specialty segment, increasing investments in promotions and branding

GSK seeks to appeal Delaware ruling allowing Zantac cases to go forward

The companies, which all sold Zantac at different times, argue that Medinilla should have granted their motion to block plaintiffs from presenting expert testimony that Zantac causes cancer

GSK Pharma Q4 results: Profit rises 45% on growth in NLEM drugs, vaccines

The board has recommended a dividend of Rs 32 per equity share on face value of Rs 10 each for the year ended 31 March 2024, subject to approval of members at 99th Annual General Meeting

GSK Pharma Q4 results: Net profit up 46% at Rs 194.48 cr on higher sales

GlaxoSmithKline Pharmaceuticals Ltd on Friday reported a 46 per cent increase in consolidated net profit at Rs 194.48 crore in the fourth quarter ended March 31, on the back of higher sales. The company had posted a net profit of Rs 133.43 crore in the corresponding quarter of the previous fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 929.8 crore as against Rs 787.45 crore in the year-ago period, it added. Total expenses in the fourth quarter were higher at Rs 691.41 crore as compared to Rs 635.54 crore in the same period a year ago. The board has recommended a dividend of Rs 32 per equity share on the face value of Rs 10 each for the year ended March 31, subject to approval of members at upcoming annual general meeting, the company said. For the fiscal ended March 31, 2024 net profit was at Rs 589.96 crore as compared to Rs 610.69 crore in the preceding year, the compa

Valuations hurdle likely to keep GSK Pharma stock under pressure

Even as the top pharmaceutical peers delivered a double digit growth in the December quarter, sales for GSK Pharma at Rs 805 crore was flat

GSK Pharma surges 7%, nears record high on healthy business outlook

Since November, the stock has appreciated by 36% after the company reported earnings improvement in Q2FY24 on strong demand for its vaccines and general medicine.

GSK's India arm posts 12.5% Q2 profit at Rs 218 cr on strong vaccine demand

Shares in GSK India closed up 0.3% ahead of results on Thursday, where the Nifty Pharma index closed down 0.03% today

Supreme Court dismisses plea against GSK pharma for deficiency in service

The top court was hearing a plea by a man challenging an order of the National Consumer Disputes Redressal Commission

HUL, GSK Asia to scrap distribution pact for OTC products by next year

In 2018, HUL had announced that GSK Consumer Healthcare will merge with HUL in an all-stock deal

GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off

The results underscore a comeback for GSK in the race to help fight the Covid-19 pandemic after it failed to bring a vaccine to the market so far

GSK Pharma's net profit falls 3.9% to Rs 150.3 cr in December quarter

The company had posted a consolidated net profit of Rs 156.51 crore in the corresponding quarter last fiscal, GlaxoSmithKline Pharmaceuticals said in a regulatory filing

Stocks to Watch:GSK Pharma, Jet Airways, Rel Infra, auto, bank, FMCG shares

Traders may keep positions light owing to the weekend factor as uncertainty lingers around the threat of Omicron variant

GSK Pharma Q3 net profit jumps over two-folds to Rs 204 crore

The company had reported a net profit of Rs 76.47 crore in the same period of the previous fiscal

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

These are scheduled drugs (or ones that are under price control) and low priced

GSK says it aims to bring FDA-approved antibody therapy to India for Covid

Treatment with Sotrovimab resulted in an 85 per cent reduction in the risk of hospitalization, says company.

GSK Pharma's growth challenges to remain in near term as Covid dents sales

Even as overall pharma market was up 5% over the year-ago period, GSK's September sales were down 8%, the firm is banking on recovery led by top brands, new launches